Read More

Sorrento Successfully Completes Phase 1 Study And Is Proceeding To Implement Global Registrational Trials With STI-1558, An Oral Mpro Inhibitor As A Standalone Oral Treatment And Prevention Of COVID-19 Without The Need For A Ritonavir Booster

Phase 1 Study (with 58 healthy volunteers) of STI-1558 was completed in Australia with 300 mg, 600 mg, 1,200 mg and 2,000 mg doses in the single ascending dose (SAD) portion of the study and 300 mg, 600 mg and 800 mg

SRNE

Read More

Gilead And MacroGenics Announce Oncology Collaboration To Develop Bispecific Antibodies; Gilead Will Pay Macrogenics An Upfront Payment Of $60M And MacroGenics Will Be Eligible To Receive Up To $1.7B In Potential Milestones

Gilead Sciences, Inc. (NASDAQ:GILD) and MacroGenics (NASDAQ:MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using

GILD

Read More

Anavex Life Sciences Announces Late-Breaking Presentation Of Phase 2b/3 Data of Oral ANAVEX 2-73 (blarcamesine) For Early Alzheimer’s Disease At Upcoming Clinical Trials On Alzheimer’s Disease (CTAD) Congress 2022

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and

AVXL

Read More

Sorrento Announces Publication Of Data In Cell Press Journal Med Describing Discovery And Preclinical Efficacy Of A Broadly-Acting SARS-CoV-2 Neutralizing Antibody Administered IV (STI-9167) Or IN (STI-9199)

Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , )))) today announced publication in the Cell Press journal Med of data detailing work relating to the discovery and preclinical profiling

SRNE